Biotechnology

Beigene

Beigene released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 1.513 B (forecast USD 1.437 B), actual EPS USD 1.9499 (forecast USD 0.7666)

BeiGene Exceeds Expectations in Q1 2026 Earnings and Profits

Beigene to Release FY2026 Q1 Earnings on May 6, Pre-Market EST; Forecast Revenue USD 1.439 B, EPS USD 0.7912

BeOne Medicines Plans to Acquire Huahui Healthcare's Cancer Therapy

BeiGene Exceeds Revenue Expectations in FY2025

Beigene to Release FY2025 Earnings on March 25 During-Market (EST), Forecast Revenue USD 5.301 B, EPS USD 3.2417

Guotai Junan and DBS Maintain Buy Rating on BeiGene

Beigene released FY2025 Q4 earnings on February 26 During-Market (EST), actual revenue USD 1.498 B (forecast USD 1.455 B), actual EPS USD 0.5233 (forecast USD 1.2193)

Beigene released FY2025 earnings on February 26 During-Market (EST), actual revenue USD 5.343 B (forecast USD 5.298 B), actual EPS USD 2.4699 (forecast USD 3.2417)

BeiGene Reports Revenue Exceeding Expectations for 2025 Fiscal Year

BeiGene Launches Novel BCL2 Inhibitor Z Orchard for Supply

BeiGene's Novel BCL2 Inhibitor Beyla® Obtains Conditional Approval from NMPA

BeiGene Establishes A-Share Raising Fund Management System

UOB Securities Analysts Positive on BeiGene's Revenue Growth Potential

Two Drugs of BeiGene Entered the Commercial Insurance Innovative Drugs Directory

BeiGene's Q3 Total Revenue Reached 1.4 Billion USD, Up 41% YoY

Beigene Reports Significant Q3 2025 Revenue Growth

CMBI Raises Profit Forecast and Maintains Buy Rating for BeiGene

BGBA's Brukinsa Surpasses Expectations, Leading in BTK Inhibitors Market

Morgan Stanley Reaffirms Buy Rating on BeiGene

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IBBQ

LABU

BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion.

benzinga_article

VG Health

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

iShares US Pharma

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

SBIO

The FDA has approved AstraZeneca's Fasenra for treating hypereosinophilic syndrome in patients aged 12 and older, based on Phase III trial data. Meanwhile, Aardvark Therapeutics faces a full clinical hold on its ARD-101 program due to safety concerns. Additionally, BeOne Medicines' CEO John Oyler discusses the company's rapid growth in oncology and its dual operating model, emphasizing the importance of speed and scientific rigor in a competitive landscape.

Pharmexec

AstraZeneca

AstraZeneca PLC

ALPS Medical Breakthrough

Aardvark Therapeutics

<![CDATA[Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra]]>

BGNE

BeOne Medicines, originally founded as BeiGene in 2010, has evolved into a global biotech company focused on making cancer treatments more accessible. Based in Basel, Switzerland, BeOne has over 12,000 employees and operates in 75 countries. Its flagship drug, Brukinsa, generated $3.9 billion in sales in 2025, contributing to total revenues of $5.3 billion and achieving net profitability for the first time. The company emphasizes efficiency in drug development and has a pipeline of over 35 clinical assets.

BeOne Medicines

BEONE MEDICINES

<![CDATA[John Oyler: Rewiring Operations in Oncology]]>

The FDA has granted accelerated approval to BeOne Medicines' Beqalzi, the first BCL2 inhibitor for relapsed mantle cell lymphoma, and Taiho Oncology's Inqovi for newly diagnosed acute myeloid leukemia. The Doceree Makers Summit highlighted the need for integrated marketing technology in pharma, while Dean Erhardt proposed AI-enabled workflow automation to improve the prior authorization system. Beqalzi showed a 52% response rate in trials, and Inqovi achieved a 41.6% complete remission rate, offering new treatment options for challenging blood cancers.

Sanofi

Bristol Myers Squibb

Eli Lilly

Bristol-Myers Squibb Company

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi]]>

The FDA has granted accelerated approval to BeOne Medicines' BEQALZI (sonrotoclax) for adults with relapsed mantle cell lymphoma after prior BTK inhibitor therapy. This approval provides a new treatment option for patients with limited therapies. The drug showed a 52% overall response rate in clinical trials. The approval is contingent on further confirmation of clinical benefit in ongoing trials. Beqalzi is also under review in Europe and has been approved in China for similar conditions. The drug is expected to launch in the second half of 2026.

S&P 500

Summit Therapeutics

BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer

BEONE MEDICINES has received accelerated FDA approval for BEQALZI (Sotokela) to treat adult patients with relapsed or refractory mantle cell lymphoma who have undergone at least two prior systemic therapies, including a BTK inhibitor. This makes BEQALZI the first BCL2 inhibitor approved in the U.S. for this condition. The drug is designed to enhance BCL2 inhibition effects, improving treatment efficacy and tolerability.

AASTOCKS News

BEONE MEDICINES  BEQALZI Receives US Approval for Treatment of Adult Lymphoma Patients

06160

Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK$234.00, while the shares closed at HK$189.90. The analyst consensus for the stock is Strong Buy, with a target consensus of HK$254.33, indicating a potential upside of 33.93%. Additionally, DBS also maintains a Buy rating with a price target of HK$290.00.

Tip Ranks

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

BeOne Medicines Ltd has received accelerated U.S. FDA approval for BEQALZI (sonrotoclax), the first BCL2 inhibitor for adults with relapsed mantle cell lymphoma after prior therapies. The drug shows a 52% overall response rate and a 16% complete response rate in trials. This approval, supported by Breakthrough and Orphan designations, enhances treatment options for patients facing this aggressive lymphoma. Analysts rate BeOne stock as a Buy with a price target of HK$290.00, reflecting confidence in the company's innovative therapies for blood cancers.

BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma

Beigene(ONC.US)